Biomea Fusion, Inc. Revenue
Biomea Fusion, Inc. (BMEA) reported Revenue of $1.24 billion for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2022-11-07
- Biomea Fusion, Inc. revenues for the quarter ending 2022-09-30 was $165.00M.
- Biomea Fusion, Inc. revenues for the quarter ending 2022-06-30 was $0.00.
- Biomea Fusion, Inc. revenues for the quarter ending 2022-03-31 was $1.07B, a 0.00% change year-over-year.
- Biomea Fusion, Inc. revenues for the quarter ending 2021-09-30 was $0.00.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month |
|---|---|---|---|
| 2022-09-30 | $165.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $165.00M derived: sum of 2 quarters · filed 2022-11-07 | $1.24B 10-Q · filed 2022-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $1.07B 10-Q · filed 2022-08-01 | |
| 2022-03-31 | $1.07B 10-Q · filed 2022-05-16 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $1.07B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.07B 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $1.07B 10-Q · filed 2021-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |